RecruitingPHASE1, PHASE2NCT05826535
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lyell Immunopharma, Inc.
- Intervention
- LYL314(drug)
- Enrollment
- 270 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2031
Study locations (28)
- University of California-Irvine Medical Center, Irvine, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles, California, United States
- Scripps Clinic, San Diego, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Louisville Brown Cancer Center, Louisville, Kentucky, United States
- Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
- Corewell Health, Grand Rapids, Michigan, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05826535 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic